Immunomodulation by Oral N-acetylglucosamine

April 15, 2016
HS# 2011-8638
Brain & Nerve, Multiple Sclerosis
Michael Demetriou, MD, PhD, FRCP(C)
ICTS (Hewitt Hall) and Gottschalk Medical Plaza (both on the UC Irvine main campus), as well as UC Irvine Medical Center.
Multiple sclerosis is an autoimmune disease where white blood cells attack the brain, resulting in neurological damage.  This research study examines whether the dietary supplement N-acetylglucosamine (GlcNAc) prevents the activities of white blood cells that promote multiple sclerosis.  Previous research has found that GlcNAc inhibits white blood cells and suppresses multiple sclerosis-like disease in animals.  Similar to the dietary supplement glucosamine, GlcNAc has been typically used to improve the structure and function of joints and relieve joint pain.  GlcNAc is approved for sale 'over the counter' in the United States as a dietary supplement by the Food and Drug Administration. GlcNAc is well tolerated with no known side effects. This current study examines whether giving GlcNAc orally to human subjects prevents the over-activity of white blood cells known to promote multiple sclerosis.
You are eligible to participate in this study if you are at least 18 years of age up to 75 years old; a non-Latino caucasian and clinically diagnosed  with multiple sclerosis on Copaxone.  A test for genetic variants associated with multiple sclerosis will also determine eligibility. You must also not currently be taking GlcNAd or glucosamine, weigh between 110 and 220 lb., not be allergic to shellfish and, if female, not be pregnant, attempting to become pregnant, 6 months  postpartum, or breast feeding following a pregnancy.
Approximately 11 hours over 11 weeks divided between 8 study visits.
There are no anticipated benefits for participants.
There is no compensation available.
Accepting Participants
Barbara Newton, MD, associate project scientist, Department of Neurology